Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up-Reference-Cited by-同舟云学术

Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up

Published:2019-12-01 Issue:12 Volume:4 Page:1261
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Stone Gregg W.¹²,Kimura Takeshi³,Gao Runlin⁴,Kereiakes Dean J.⁵,Ellis Stephen G.⁶,Onuma Yoshinobu⁷,Chevalier Bernard⁸,Simonton Charles⁹,Dressler Ovidiu¹⁰,Crowley Aaron¹⁰,Ali Ziad A.¹⁰²,Serruys Patrick W.¹¹

Affiliation:

1. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York

2. The Cardiovascular Research Foundation, New York, New York

3. Kyoto University Hospital, Kyoto, Japan

4. Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China

5. The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio

6. Cleveland Clinic, Cleveland, Ohio

7. Erasmus Medical Center, Rotterdam, the Netherlands

8. Institut Cardiovasculaire Paris Sud, Massy, France

9. Abbott Vascular, Santa Clara, California

10. Columbia University Medical Center, New York, New York

11. International Centre for Cardiovascular Health, Imperial College, London, England

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2752439/jamacardiology_stone_2019_oi_190071.pdf

Reference34 articles.

1. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.;Yamaji;Eur Heart J,2016

2. 5-Year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).;Gada;JACC Cardiovasc Interv,2013

3. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation.;Yamaji;Circ Cardiovasc Interv,2010

4. Incidence and long-term clinical impact of late-acquired stent fracture after sirolimus-eluting stent implantation in narrowed coronary arteries.;Kuramitsu;Am J Cardiol,2017

5. Incidence and clinical impact of stent fracture after PROMUS element platinum chromium everolimus-eluting stent implantation.;Kuramitsu;JACC Cardiovasc Interv,2015

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis;JACC: Cardiovascular Interventions;2024-08

2. Review of late-breaking clinical trials from Cardiovascular Research Technologies (CRT) 2024;Cardiovascular Revascularization Medicine;2024-08

3. Long-term outcomes following bioresorbable vascular scaffolds;Expert Review of Cardiovascular Therapy;2024-07-30

4. Bioresorbable scaffolds: past and present. Clinical example of a 10-year follow-up of a patient with an implanted Absorb stent;Ateroscleroz;2024-07-05

5. The Absorb GT1 Bioresorbable Vascular Scaffold System　― 5-Year Post-Market Surveillance Study in Japan ―;Circulation Journal;2024-05-24